U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H22ClN5O.ClH
Molecular Weight 408.3254
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAZODONE HYDROCHLORIDE

SMILES

c1ccn2c(c1)nn(CCCN3CCN(CC3)c4cccc(c4)Cl)c2=O.Cl

InChI

InChIKey=OHHDIOKRWWOXMT-UHFFFAOYSA-N
InChI=1S/C19H22ClN5O.ClH/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25;/h1-3,5-7,9,15H,4,8,10-14H2;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H22ClN5O
Molecular Weight 371.8645
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00656 | https://www.drugs.com/trazodone.html | http://reference.medscape.com/drug/oleptro-trazodone-d-342965

Trazodone (brand name Oleptro, Desyrel, etc) is a serotonin uptake inhibitor that is used as an antidepressive agent. Trazodone binds to the 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at the H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS. Because of its lack of anticholinergic side effects, trazodone is especially useful in situations in which antimuscarinic effects are particularly problematic (e.g., in patients with benign prostatic hyperplasia, closed-angle glaucoma, or severe constipation). Trazodone's propensity to cause sedation is a dual-edged sword. For many patients, the relief from agitation, anxiety, and insomnia can be rapid; for other patients, including those individuals with considerable psychomotor retardation and feelings of low energy, therapeutic doses of trazodone may not be tolerable because of sedation. Trazodone elicits orthostatic hypotension in some patients, probably as a consequence of α1-adrenergic receptor blockade. Mania has been observed in association with trazodone treatment, including in patients with bipolar disorder, as well as in patients with previous diagnoses of major depression. Compared to the reversible MAOI antidepressant drug moclobemide, significantly more impairment of vigilance occurs with trazodone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
17.0 nM [IC50]
223.87 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DESYREL

Approved Use

Trazodone Hydrochloride Tablets USP are indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of Trazodone Hydrochloride Tablets USP has been established in trials with the immediate release formulation of trazodone [see Clinical Studies (14)

Launch Date

3.78000015E11
Primary
DESYREL

Approved Use

Trazodone Hydrochloride Tablets USP are indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of Trazodone Hydrochloride Tablets USP has been established in trials with the immediate release formulation of trazodone [see Clinical Studies (14)

Launch Date

3.78000015E11
Primary
DESYREL

Approved Use

Trazodone Hydrochloride Tablets USP are indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of Trazodone Hydrochloride Tablets USP has been established in trials with the immediate release formulation of trazodone [see Clinical Studies (14)

Launch Date

3.78000015E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.88 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13.3 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.8 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
unknown, oral
TRAZODONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
methyltestosterone(200 mg)
Sources:
unknown, 22 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Drowsiness, Hypertension...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1 patient)
Hypertension (1 patient)
Vomiting (1 patient)
Sources:
2900 mg single, oral
Overdose
Dose: 2900 mg
Route: oral
Route: single
Dose: 2900 mg
Co-administed with::
alprazolam(8 mg)
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Dry mouth, Upset stomach...
AEs leading to
discontinuation/dose reduction:
Dry mouth (1 patient)
Upset stomach (1 patient)
Drowsiness (1 patient)
Sources:
6450 mg single, oral
Overdose
Dose: 6450 mg
Route: oral
Route: single
Dose: 6450 mg
Sources:
unknown, 37 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Seizures, Hyponatremia...
AEs leading to
discontinuation/dose reduction:
Seizures (grade 5, 1 patient)
Hyponatremia (grade 5, 1 patient)
Sources:
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
unknown, 55 years
n = 1
Health Status: unknown
Age Group: 55 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Arrhythmia...
AEs leading to
discontinuation/dose reduction:
Arrhythmia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
methyltestosterone(200 mg)
Sources:
unknown, 22 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
Hypertension 1 patient
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
methyltestosterone(200 mg)
Sources:
unknown, 22 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
methyltestosterone(200 mg)
Sources:
unknown, 22 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
Drowsiness 1 patient
Disc. AE
2900 mg single, oral
Overdose
Dose: 2900 mg
Route: oral
Route: single
Dose: 2900 mg
Co-administed with::
alprazolam(8 mg)
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Dry mouth 1 patient
Disc. AE
2900 mg single, oral
Overdose
Dose: 2900 mg
Route: oral
Route: single
Dose: 2900 mg
Co-administed with::
alprazolam(8 mg)
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Upset stomach 1 patient
Disc. AE
2900 mg single, oral
Overdose
Dose: 2900 mg
Route: oral
Route: single
Dose: 2900 mg
Co-administed with::
alprazolam(8 mg)
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Hyponatremia grade 5, 1 patient
Disc. AE
6450 mg single, oral
Overdose
Dose: 6450 mg
Route: oral
Route: single
Dose: 6450 mg
Sources:
unknown, 37 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Seizures grade 5, 1 patient
Disc. AE
6450 mg single, oral
Overdose
Dose: 6450 mg
Route: oral
Route: single
Dose: 6450 mg
Sources:
unknown, 37 years
n = 1
Health Status: unknown
Condition: suicide attempt
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Arrhythmia 1 patient
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
unknown, 55 years
n = 1
Health Status: unknown
Age Group: 55 years
Sex: F
Population Size: 1
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes
yes (co-administration study)
Comment: [PMID:7482685]: CYP2D6-mediated metabolism of trazodone is inhibited by coadministration of thioridazine, which is an inhibitor of this isozyme.
yes
yes (co-administration study)
Comment: [DESYREL® LABEL]: The concomitant use of DESYREL and strong CYP3A4 inhibitors increased the exposure of trazodone compared to the use of DESYREL alone. The concomitant use of DESYREL and strong CYP3A4 inducers decreased the exposure of trazodone compared to the use of DESYREL alone.
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Lethal combination of tramadol and multiple drugs affecting serotonin.
2000 Dec
Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba.
2000 May
Fluoxetine-induced sexual dysfunction reversed by trazodone.
2000 Nov
Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone.
2001
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.
2001
Inhibition of K(+)-evoked release of rat striatal 5-hydroxytryptamine by an atypical antidepressant: trazodone.
2001
The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism.
2001 Apr
Use of drugs by Old Age Psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia.
2001 Aug
Central nervous system agents in the treatment of erectile dysfunction: how do they work?
2001 Dec
[Depressive disorders in neurologic rehabilitation: therapy with paroxetine].
2001 Jan
Weight outcomes among antidepressant users in nursing facilities.
2001 Jan
Serotonin syndrome. A common but often unrecognized psychiatric condition.
2001 Jan
P-glycoprotein interactions of nefazodone and trazodone in cell culture.
2001 Jul
Fatal overdose with trazodone: case report and literature review.
2001 Jul-Aug
Pharmacology of erectile function and dysfunction.
2001 May
Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients.
2001 May
Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic.
2002
Citalopram-induced priapism.
2002 Apr
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
2002 Apr
Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.
2002 Aug
Alpha(1)-adrenoceptor antagonists. 4. Pharmacophore-based design, synthesis, and biological evaluation of new imidazo-, benzimidazo-, and indoloarylpiperazine derivatives.
2002 Aug 15
Alterations in 5-HT(1A) receptors and adenylyl cyclase response by trazodone in regions of rat brain.
2002 Aug 16
Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone.
2002 Feb
Early polyneuropharmacologic intervention in brain injury agitation.
2002 Feb
An 8-year-old boy with autism, 1 year later.
2002 Jan 23-30
Masturbatory guilt leading to severe depression and erectile dysfunction.
2002 Jul-Sep
[Chronobiological research on antidepressant drugs: the effect of the antidepressant drugs, trazodone and imipramine on the circadian rhythm using electroencephalography in healthy volunteers].
2002 Jun
[Progress in therapy of erectile dysfunction. New orally administered drugs].
2002 May
Psychotropic drugs and the ECG: focus on the QTc interval.
2002 May
[Latest therapies for treating dementia].
2002 May 15
[Depression in epilepsy: symptom or syndrome?].
2002 Nov-Dec
Erectile dysfunction: oral pharmacotherapy options.
2002 Sep
No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
2002 Summer
Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum.
2003 Mar 10
A fatal drug interaction between oxycodone and clonazepam.
2003 May
Patents

Sample Use Guides

Starting dose: 150 mg once daily. May be increased by 75 mg per day every three days. Maximum dose: 375 mg per day
Route of Administration: Oral
In Vitro Use Guide
The receptors affinity was estimated at Nova Screen Laboratories by the ability of the Trazodone to displace selective radioligands. The assays were carried out using the following: for 5HT2A – rat cortical membranes, [3H]ketanserin (1.0 nM) as radioligand and methysergide as reference compound; for alpha1 - rat cortical membranes, [3H]prazosin (0.5 nM) and prazosin; for 5HT-R - rat forebrain membranes, [3H]citalopram (0.7 nM) and imipramine. In the preliminary binding assay, the results are expressed as inhibition percentage compared to results without drug and represent the average of duplicate tubes at each tested concentration in a single experiment.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:56:22 UTC 2021
Edited
by admin
on Fri Jun 25 20:56:22 UTC 2021
Record UNII
6E8ZO8LRNM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRAZODONE HYDROCHLORIDE
HSDB   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TRAZODONE HYDROCHLORIDE [MART.]
Common Name English
TRAZODONE HYDROCHLORIDE [USP-RS]
Common Name English
DESYREL
Brand Name English
AF-1161
Code English
TRAZODONE HYDROCHLORIDE [MI]
Common Name English
2-(3-(4-(M-CHLOROPHENYL)-1-PIPERAZINYL)PROPYL)-S-TRIAZOLO(4,3-A)PYRIDIN-3(2H)-ONE MONOHYDROCHLORIDE
Systematic Name English
1,2,4-TRIAZOLO(4,3-A)PYRIDIN-3(2H)-ONE, 2-(3-(4-(3-CHLOROPHENYL)-1-PIPERAZINYL)PROPYL)-, MONOHYDROCHLORIDE
Common Name English
TRAZODONE HYDROCHLORIDE [VANDF]
Common Name English
TRAZODONE HYDROCHLORIDE [HSDB]
Common Name English
TRAZODONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
TRAZODONE HYDROCHLORIDE [JAN]
Common Name English
TRAZODONE HYDROCHLORIDE [USAN]
Common Name English
TRAZODONE HCL
Common Name English
TRAZODONE HYDROCHLORIDE [WHO-DD]
Common Name English
NSC-292811
Code English
TRAZODONE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
Code System Code Type Description
CAS
25332-39-2
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
NCI_THESAURUS
C47767
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
RXCUI
82112
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY RxNorm
EPA CompTox
25332-39-2
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
DRUG BANK
DBSALT000344
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
PUBCHEM
62935
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
FDA UNII
6E8ZO8LRNM
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL621
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
USP_CATALOG
1673500
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M11010
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
246-855-5
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
EVMPD
SUB15596MIG
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
HSDB
25332-39-2
Created by admin on Fri Jun 25 20:56:22 UTC 2021 , Edited by admin on Fri Jun 25 20:56:22 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
UNSPECIFIED
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY